Alain Vertes interview and outlook on the future pathway of Medicine and Stem Cells is just further reinforcement of the opportunities that lie ahead.
His discussion on stell cells and its reference to Monoclonal antibodies in the context of Biotech valuations is for everyone to make there own opinions about and reflect how todays Biotech's in Regenerative Medicine are valued.
http://www.thelifesciencesreport.co...s-measure-up-nxr-biotechnologies-alain-vert-s
GLTAH - 2015.
The Life Sciences Report: 17/3/15
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 97.0¢ | $1.01 | 96.5¢ | $7.757M | 7.884M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 274918 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 974 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |